The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). Due to the progressive nature of PD...
Copyright © 2023 cape-breton.com. Toady's News. All Rights Reserved